ProCE Banner Activity

Optimizing Outcomes for Relapsed/Refractory CLL/SLL and MCL


Download this slideset featuring expert perspectives on the latest in BTK inhibitor therapy for patients with relapsed/refractory CLL and MCL.

Released: October 30, 2023

Expiration: October 29, 2024



Kami Maddocks

Kami Maddocks, MD

Professor-Clinical, Division of Hematology
Director, Lymphoma Program
Associate Division Director for Ambulatory Operations, Division of Hematology
Medical Director, Infusion Services
Associate Chief Medical Officer, The James Cancer Hospital
Chief of Staff – Elect, The James Cancer Hospital
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Jennifer Woyach

Jennifer Woyach, MD

D Warren Brown Professor of Leukemia Research
Section Head, CLL and Hairy Cell Leukemia
Associate Division Director for Clinical Research
Division of Hematology
Co-Leader Leukemia Research Program
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


This activity is supported by an educational grant from Lilly.